Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2022 | Looking forward to ISA 2022

Joan Bladé • 12 May 2022
COMy 2022
Amyloidosis Multiple Myeloma Rare Diseases

In this video, Joan Bladé, MD, PhD, University of Barcelona, Barcelona, Spain, discusses the upcoming meeting of the International Society of Amyloidosis (ISA) being held in Heidelberg on September 4-8, 2022. Prof Bladé briefly discusses previous ISA meetings and further emphasizes the importance of these meetings as an educational platform for amyloidosis. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Disclosures

Honoraria for lectures: Janssen, BMS, Amgen, Takeda, Oncopeptides

More from Joan Bladé

How the amyloidosis treatment landscape has transformed in recent years 1:02
How the amyloidosis treatment landscape has transformed in recent years
Joan Bladé • 12 May 2022
Managing and treating renal impairment in multiple myeloma 3:26
Managing and treating renal impairment in multiple myeloma
Joan Bladé • 12 May 2022
Amyloidosis classification and epidemiology 3:05
Amyloidosis classification and epidemiology
Joan Bladé • 4 Sep 2020
ISA 2020: continuing the amyloidosis conversation 10:09
ISA 2020: continuing the amyloidosis conversation
Joan Bladé • 2 Sep 2020

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals